What first‑line medications can be used in an adult patient seeking treatment for alcohol cravings, and what liver and renal safety considerations should be taken into account?

Medications for Alcohol Cravings

First-Line Pharmacotherapy Selection

For patients without liver disease, initiate either naltrexone 50 mg daily or acamprosate 666 mg three times daily (1,998 mg/day total), starting 3-7 days after the last drink and only after complete resolution of withdrawal symptoms. 1

Naltrexone (Harm Reduction Focus)

• Naltrexone is most effective at reducing heavy drinking episodes and drinking frequency rather than promoting complete abstinence, with a number needed to treat of approximately 20 to prevent return to any drinking. 2, 3
• Start with 25 mg daily for days 1-3, then increase to 50 mg daily for 3-6 months (up to 12 months). 4
• An extended-release intramuscular formulation (380 mg monthly) is available and demonstrates superior efficacy to placebo in reducing heavy drinking events when combined with psychosocial therapy. 2, 5
• The mechanism involves mu-opioid receptor antagonism, which blocks the rewarding effects of alcohol and reduces impulsive use. 2

Acamprosate (Abstinence Focus)

• Acamprosate is equally effective as naltrexone but works through glutamatergic NMDA receptor modulation, making it particularly suitable for patients prioritizing complete abstinence over harm reduction. 1, 3
• Dosing is 666 mg three times daily (total 1,998 mg/day) for patients weighing ≥60 kg. 4
• Meta-analysis of 24 randomized controlled trials confirms efficacy, with a number needed to treat of approximately 12. 2

---

Critical Safety Considerations

Hepatic Safety Profile

Naltrexone carries significant hepatotoxicity risk and is absolutely contraindicated in patients with alcoholic liver disease, acute hepatitis, or any degree of cirrhosis. 1, 4

• Naltrexone undergoes hepatic metabolism and has been associated with hepatic injury at therapeutic doses. 2
• Obtain baseline liver function tests before initiating naltrexone and monitor every 3-6 months during treatment. 2, 1
• Do not prescribe naltrexone to patients with any elevation of liver enzymes or hepatic dysfunction from alcohol. 4

Acamprosate has no hepatic metabolism and carries zero hepatotoxicity risk, making it safe across all stages of liver disease. 2, 1

• Acamprosate is the preferred first-line agent when hepatic status is uncertain or when any degree of liver dysfunction exists. 4
• No reported instances of hepatotoxicity have occurred with acamprosate use. 2

Renal Safety Profile

Acamprosate is contraindicated in severe renal impairment (creatinine clearance ≤30 mL/min) and requires dose reduction for moderate impairment (30-50 mL/min). 1, 4

• Acamprosate is excreted entirely renally without metabolism. 2
• Always evaluate creatinine clearance before initiating acamprosate. 4

Naltrexone is primarily renally excreted but does not require dose adjustment in renal impairment. 2

---

Special Population: Patients with Alcoholic Liver Disease

For patients with cirrhosis or alcoholic liver disease, baclofen is the only medication with proven safety and efficacy in randomized controlled trials. 2, 1

Baclofen Protocol

• Dosing ranges from 30-80 mg/day (typically 10 mg three times daily), titrated gradually over 12 weeks. 2, 4
• A randomized trial in patients with both compensated and decompensated cirrhosis demonstrated improved total abstinence rates and decreased relapse compared to control during 1 year of observation. 2
• Baclofen works as a GABA-B receptor agonist to reduce craving and relapse risk. 4
• Use caution and slower titration in severe liver disease, and exclude patients with hepatic encephalopathy, as baclofen may impair mentation. 2

Gabapentin as Second-Line

• Gabapentin 1,800 mg/day (600 mg three times daily) is a second-line option for patients with liver disease, with a number needed to treat of 8 for abstinence and 5 for non-excessive drinking. 1, 4
• Gabapentin has no hepatic metabolism and is entirely renally excreted. 2
• Monitor closely for renal dysfunction and worsening mental status/sedation. 2

---

Medications to Avoid

Disulfiram should be avoided in severe alcoholic liver disease due to potential hepatotoxicity. 2, 4

• While disulfiram shows mixed evidence for reducing drinking frequency (grade B evidence), its hepatotoxic potential makes it unsuitable for patients with liver disease. 2, 3

---

Critical Timing and Withdrawal Management

Never initiate naltrexone, acamprosate, or baclofen during active alcohol withdrawal—doing so offers no benefit and delays appropriate benzodiazepine therapy. 4

• Benzodiazepines are the gold-standard treatment for acute alcohol withdrawal syndrome, effectively reducing symptoms and preventing seizures and delirium tremens. 4
• In patients with hepatic dysfunction, prefer short- or intermediate-acting benzodiazepines (lorazepam 1-4 mg every 4-8 hours or oxazepam) over long-acting agents. 4
• Administer thiamine 100-300 mg daily for 4-12 weeks before any intravenous glucose to prevent Wernicke-Korsakoff encephalopathy. 4
• Initiating naltrexone during withdrawal can precipitate a hyper-acute withdrawal syndrome due to opioid-receptor antagonism. 4

---

Treatment Algorithm

Step 1: Assess hepatic and renal function before selecting medication. 1

Step 2: For patients WITHOUT significant liver disease:

• Choose naltrexone 50 mg daily (harm reduction focus) OR acamprosate 1,998 mg/day (abstinence focus). 1
• If renal impairment (CrCl ≤50 mL/min), select naltrexone over acamprosate. 4
• If any hepatic dysfunction or uncertainty about liver status, select acamprosate over naltrexone. 4

Step 3: For patients WITH alcoholic liver disease or cirrhosis:

• Use baclofen 30-80 mg/day as first-line therapy. 1, 4
• Consider gabapentin 1,800 mg/day as second-line. 1
• Absolutely avoid naltrexone and disulfiram. 1, 4

Step 4: Combine all pharmacotherapy with psychosocial interventions (cognitive-behavioral therapy, motivational enhancement therapy, or 12-step facilitation). 2, 4

---

Expected Outcomes

When paired with psychosocial treatment, naltrexone and acamprosate reduce relapse rates from 54-60% to 23-31%, though effect sizes are modest (0.15-0.20). 4

Sustained abstinence improves outcomes across all stages of alcoholic liver disease, lowering portal pressure and preventing progression to cirrhosis. 4